Document:

Exhibit 10.3

 

PATENT CROSS-LICENSING AGREEMENT

 

between

 

BEGO Medical GmbH

Technologiepark Universität,

Wilhelm-Herbst-Straße 1, 28359 Bremen,

 

- hereinafter referred to as BEGO -

 

and

 

VOXELJET technology GmbH

Paul-Lenz-Strasse 1, 86316 Friedberg

 

- hereinafter referred to as VOXELJET -

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

1

 

PREAMBLE

 

Whereas BEGO is a manufacturer of customised and industrially made Prosthetic Dentistry centrally in Bremen and distributes it to dental engineering labs.  Whereas BEGO is applying a globally unique rapid prototyping method for making Prosthetic Dentistry from biocompatible metallic alloys.  Whereas BEGO MEDICAL is an affiliate company of BEGO DENTAL which for 120 years has successfully been making dental engineering products in Bremen and distributing them throughout the world.

 

Whereas VOXELJET is active in the field of development, manufacturing and distribution of industrial 3D Printers for tool-less and fully automated manufacturing of components made of plastic and moulding sand.  Whereas VOXELJET furthermore operates a service centre with such 3D Printers for on-demand manufacturing of moulding sand for metal cast as well as plastic moulding and functional models made of plastic.

 

Whereas VOXELJET is interested in obtaining from BEGO a licence with respect to certain industrial property rights defined in more detail below.

 

Whereas BEGO in turn is interested in obtaining from VOXELJET a licence with respect to certain property rights also defined in more detail below.

 

Whereas BEGO furthermore is interested in exploiting its patents as well as licenced VOXELJET patent rights by awarding licences to Third Parties (“Licensing Scheme”).

 

Whereas VOXELJET is interested in this Licensing Scheme not limiting and restricting marketing of VOXELJET products and services as well as its customer relationships and unless the Licensing Scheme would conflict with the interests of VOXELJET, in particular by immediate competitors of VOXELJET being given an opportunity of circumvention.

 

Whereas it is explicitly understood by the Parties that this licensing agreement shall neither directly nor indirectly constitute an implicit licence with respect to property rights of the Parties other than those explicitly mentioned thereon granted to the respective contracting Party or Third Parties. Now, therefore, BEGO and VOXELJET herewith enter into the following Patent Licensing Agreement.

 

Section 1                                             DEFINED TERMS

 

For the purposes of this Agreement, the following terms shall be defined as follows:

 

1.1                               “Field of Application” means

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

2

 

·                                          relative to VOXELJET — the development, manufacturing, marketing, sale and other type of use of the Contractual Products and the Contractual Processes for the operation of the Contractual Products according to the principle of 3D Printing, however, not for use and/or distribution to customers in the field of Dental Applications (“VOXELJET Field of Application”) as well as

 

·                                          relative to BEGO — the development, manufacturing, sale and other use of the Contractual Products and Contractual Processes for additive manufacturing in the field of Dental Applications and for additive manufacturing with the exception of additive manufacturing under the 3D Printing principle for any other applications (“BEGO Field of Application”).

 

1.2                               “Dental Application” is defined as manufacturing of Prosthetic Dentistry, Dental Auxiliary Parts or Dental Casts as well as Drill Jigs.

 

1.3                               “Prosthetic Dentistry”: restoring of closed row of teeth and thus restoring of chewing ability to original state by inserting artificial dental crowns (crown prosthetic dentistry), bridge prosthetic dentistry or a dental prosthesis. The term of Fixed Prosthetic Dentistry comprises crown prosthetic dentistry and bridge prosthetic dentistry made of metal or ceramics which by means of dental cement is cemented on the ground tooth stumps or on dental implants. This includes but is not limited to the following: crown prosthetic dentistry, bridge prosthetic dentistry, post crowns, veneer crowns and abutments. A Prosthesis ranges from (i) a model cast denture with a cast retaining and support element to (ii) a comfortable version like a telescopic denture seated on crowned teeth.

 

1.4                               “Dental Auxiliary Parts” are required for tooth preservation in restorative dentistry. This includes but is not limited to fillings and cast fillings including inlays and various other versions like on-lays and over-lays.

 

1.5                               “Dental Casts” are casts of the jaw and/or the teeth and reflect the shape and arrangement of the teeth in the patient’s mouth without three-dimensional variance. Dental Casts serve as a planning aid for dentists and as a basis of the dental engineer’s work. Dental Casts are defined in particular as but are not limited to diagnostic casts, original dies, functional models, repair models, counterbite models, master dies, saw-cut models or die models.

 

1.6                               “Drill Jigs” are positioning aids for implants and are used by the dentist for the purpose of navigated implantation of dental implants. The jigs are designed on the basis of (3D) X-ray data and grafted on the existing bone, mucous membrane or residual tooth. With the help of the guides integrated in the Drill Jig, the drill and implant are guided to the pre-defined position.

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

3

 

1.7                               The term “Third Party” comprises every individual or legal entity with the exception of the party concerned and its Affiliated Companies.

 

1.8                               The “Effective Date” of this Agreement is the date on which this Agreement has been signed by the duly authorised representatives of both Parties. If the Agreement has not been signed by both Parties on the same day, the Effective Date is the later of the two dates of execution.

 

1.9                               “Licenced BEGO Patent Rights” are patents, utility models as well as applications for them, issuing thereof, their substitutes, renewal, confirmation and reissue as well as the patents applied for or issued internationally based on the priority of these patent or utility model applications listed in Annex 1 as well as divisional applications based thereon or derivations from them.

 

1.10                        “Licenced VOXELJET Patent Rights” are patents, utility models as well as applications for them, issuing thereof, their substitutes, renewal, confirmation and reissue as well as the patents applied for or issued internationally based on the priority of these patent or utility model applications listed in Annex 2 as well as divisional applications based thereon or derivations from them.

 

1.11                        “Net Selling Price” is the amount that a Third Party is invoiced for the acquisition of a Contractual Product or the amount that is invoiced by an Affiliated Company, sub-licensee or distributor.

 

Use for own purposes or Acquisition by an Affiliated Company must be based on an amount that has been defined at arm’s length.

 

For the purposes of paragraph 4.3, paragraph 1.9 shall apply mutatis mutandis relative to Consumables.

 

The term Acquisition shall also include renting in terms of precarium for a limited time which directly or indirectly serves the purpose of acquisition.

 

The following items shall be deducted from the amount thus determined to the extent such discount is actually granted or separately allocated to the Contractual Product by the seller in application of generally accepted accounting standards; for an exemplary calculation see Annex 3.

 

(i)                                     Value-added tax and excise duty paid by the seller, customs and other public charges that are levied on the manufacturing, import, usage or sale of the Contractual Products;

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

4

 

(ii)                                  customary quantity and cash discounts, customary commissions and dealer compensation or discount granted for buying the Contractual Product;

 

(iii)                               credit notes issued to customers for Contractual Products returned or for price reductions with subsequent effect concerning the Contractual Products;

 

(iv)                              costs of transportation, transport insurance and packaging if they are an integral part of the purchasing price of a Contractual Product invoiced to the Third Party on condition that the discount does not exceed the difference between the purchasing price invoiced to the Third Party and the average purchasing price that Third Parties pay excluding transport, insurance and packaging costs in the respective country.

 

1.12                        “Consumables” are all materials that are processed or finished in application of the Contractual Processes.

 

1.13                        “Party/Parties”, depending on the respective context, are either BEGO or VOXELJET or BEGO and VOXELJET together.

 

1.14                        “Patent claim” is defined as any claim from an issued and not yet expired licenced patent right or utility model which has not been revoked, withdrawn or declared nil and void in part or as a whole by a court or an authority entitled to do so by way of a decision against which no legal redress i.e. appeal has been lodged or may be lodged and concerning which no waiver was declared.

 

1.15                        “Improvement Inventions” is defined as any inventions, adaptations and amendments of the licenced patent rights that relate to the Contractual Products which

 

(i)                                     improve the effect or effectiveness of the Contractual Products;

 

(ii)                                  minimise side effects or any other negative consequential effects of the Contractual Products; or

 

(iii)                               reduce costs and/or enhance efficiency or improve manufacturing in manufacturing and the manufacturing process of the Contractual Products.

 

1.16                        “Affiliated Companies” with respect to each and every contractual party are defined as any person, company, corporation and any other association

 

(i)                                     in which one of the Parties directly or indirectly holds at least fifty per cent (50%) of the voting shares,

 

	
 
    	
 
    	
 
    
	
[***]
    	
Certain information in this   document has been omitted and filed separately with the Securities and   Exchange Commission. Confidential treatment has been requested with respect   to the omitted portions.
    

 

5

 

(ii)                                  which directly or indirectly holds at least fifty per cent (50%) of the voting shares in one of the Parties,

 

(iii)                               if at least fifty per cent (50%) of the voting stock is held directly or indirectly by a person, company, corporation or any other association which in turn directly or indirectly holds at least fifty per cent (50%) of the voting stock of a Party.

 

For the purposes of paragraph 1.13, relative to BEGO, the controlling shareholders shall be the contracting party.

 

1.17                        “Agreement” is defined as this Patent Licensing Agreement as well as any annexes thereto.

 

1.18                        “Territory” is defined as any countries in which BEGO is allowed to use the Licenced VOXELJET Patent Rights and/or VOXELJET is allowed to use the Licenced BEGO Patent Rights. These are the countries in which the Licenced BEGO Patent Rights and the Licenced VOXELJET Patent Rights exist.

 

1.19                        “Production Site” is defined as the place where the respective Party is allowed to manufacture the Contractual Products, namely

 

·                                          relative to VOXELJET 86316 Friedberg; and

 

·                                          relative to BEGO 28359 Bremen

 

as well as any future production sites located within the Territory. Changes in the Production Site to outside the Territory shall be subject to the respective other Party’s consent.

 

1.20                        “Contractual Products” are the products for which BEGO is allowed to use the Licenced VOXELJET Patent Rights or for which VOXELJET is allowed to use the Licenced BEGO Patent Rights in equivalent form and/or in an indirect way, namely every machine or part of a machine, in particular but not limited to the VOXELJET VX Concept plant.

 

1.21                        “Contractual Process” means the application of the processes that form the subject-matter of the Licenced BEGO Patent Rights and the Licenced VOXELJET Patent Rights respectively.

 

1.22                        “Confidential Information” is defined as know-how, all the data and information of the Parties including development data that is not in the public domain and relates to the Contractual Products, the Field of Application, the company, the research and development activities and results, the financial situation, contractual relationships or the

 

	
 
    	
 
    	
 
    
	
[***]
    	
Certain information in this   document has been omitted and filed separately with the Securities and   Exchange Commission.  Confidential   treatment has been requested with respect to the omitted portions.
    

 

6

 

business of the Parties. The term Confidential Information also includes the existence as well as the terms and conditions of this Agreement.

 

1.23                        “3D Printing” describes an additive manufacturing process in the context of which first in a process room a particle material is applied as a thin, homogeneous layer and a bonding material is subsequently selectively released to pre-defined areas of the homogeneous layer in the process room by means of a printer head which areas conform to the cross-section of a product in the respective layer for the purpose of solidifying these pre-defined areas of the layer. A description of this process, for instance, is included in the German patent application DE 10 2010 015 451 Al.

 

Section 2                                             Licence

 

2.1                               BEGO herewith grants VOXELJET the exclusive right to use the Licenced BEGO Patent Rights for the development, manufacturing at the Production Site, marketing, sale and other type of usage of Contractual Products in application of the Contractual Processes in the VOXELJET Field of Application and in the Territory subject to the provisions and limitations of this Agreement.

 

2.2                               VOXELJET herewith grants BEGO the exclusive right to use the Licenced VOXELJET Patent Rights for the development, manufacturing at the Production Site, marketing, sale and other type of usage of Contractual Products in application of the Contractual Processes in the BEGO Field of Application and in the Territory subject to the provisions and limitations of this Agreement.

 

2.3                               An exclusive right within the meaning of paragraphs 2.1 and 2.2 is defined as a Party and its Affiliated Companies reserving the right to use own patent rights themselves in their own field of application for the purposes of development, manufacturing, marketing, sale and any other type of use of Contractual Products. Otherwise the Parties shall not use or sub-licence their respective patent rights outside the fields of application allocated to them.

 

2.4                               VOXELJET has the right to grant sub-licences to an Affiliated Company all the Licenced BEGO Patent Rights under this Agreement in line with paragraph 2.1 and with respect to manufacturing, usage, marketing and sale of the Contractual Products in application of the Contractual Processes to grant sub-licences to any Third Party.

 

2.5                               BEGO has the right to grant sub-licences to an Affiliated Company all the Licenced VOXELJET Patent Rights under this Agreement in line with paragraph 2.2 and with respect to manufacturing, usage, marketing and sale of the Contractual Products in

 

	
 
    	
 
    	
 
    
	
[***]
    	
Certain information in this   document has been omitted and filed separately with the Securities and   Exchange Commission.  Confidential   treatment has been requested with respect to the omitted portions.
    

 

7

 

application of the Contractual Processes to grant sub-licences all the Licenced VOXELJET Patent Rights to any Third Party.

 

Section 3                                             Rights With Respect to Improvements

 

3.1                               BEGO is the owner of any Improvement Inventions developed by it and VOXELJET shall not obtain any rights and licences with respect to the Improvement Inventions except the powers listed in the following.

 

3.2                               Should BEGO, its Affiliated Companies or sub-licensees during the term of this Agreement make Improvement Inventions relating to the usage of the Contractual Products in the Field of Application, BEGO agrees to notify VOXELJET of the Improvement Inventions in due time in writing and place at VOXELJET’s disposal a data package that in BEGO’s opinion comprises all the information, know-how and other data that is required by VOXELJET for being able to use the Improvement Inventions for development, manufacturing, marketing, sale and/or any other use of products without prejudice to BEGO’s licences under this Agreement. BEGO herewith grants VOXELJET a non-exclusive, perpetual, gratuitous licence to use the Improvement Inventions and any information, know-how and other data that relate to the Improvement Inventions and that were placed at VOXELJET’s disposal by BEGO and grant sub-licences thereto in line with paragraph 2.4. This shall be without prejudice to BEGO’s undertaking in the event of awarding licences in the VOXELJET Field of Application in or the disposal of Improvement Inventions to Third Parties prior to conclusion of contract with the Third Party to notify VOXELJET in writing of the conditions for the respective legal transaction as well as to submit to VOXELJET an offer to enter into a licensing and purchasing agreement with VOXELJET subject to the same conditions. BEGO agrees to allow VOXELJET a period of six weeks to accept this offer; the offer must be accepted in writing (“Pre-emptive Right”).

 

3.3                               VOXELJET is the owner of any Improvement Inventions developed by it and BEGO shall not obtain any rights and licences with respect to the Improvement Inventions except the powers listed in the following.

 

3.4                               Should VOXELJET, its Affiliated Companies or sub-licensees during the term of this Agreement make Improvement Inventions relating to the usage of the Contractual Products in the Field of Application, VOXELJET agrees to notify BEGO of the Improvement Inventions in due time in writing and place at BEGO’s disposal a data package that in VOXELJET’s opinion comprises all the information, know-how and other data that is required by BEGO for being able to use the Improvement Inventions for development, manufacturing, marketing, sale and/or any other use of products without prejudice to VOXELJET’s licences under this Agreement. VOXELJET herewith grants

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

8

 

BEGO a non-exclusive, perpetual, gratuitous licence to use the Improvement Inventions and any information, know-how and other data that relate to the Improvement Inventions and that were placed at BEGO’s disposal by VOXELJET and grant sub-licences thereto in line with paragraph 2.5. This shall be without prejudice to VOXELJET’s undertaking in the event of awarding licences in the BEGO Field of Application in or the disposal of Improvement Inventions to Third Parties prior to conclusion of contract with the Third Party to notify BEGO in writing of the conditions for the respective legal transaction as well as to submit to BEGO an offer to enter into a licensing and purchasing agreement with BEGO subject to the same conditions. VOXELJET agrees to allow BEGO a period of six weeks to accept this offer; the offer must be accepted in writing (“Pre-emptive Right”).

 

Section 4                                             Remuneration

 

4.1                               In consideration of granting of the Licenced BEGO Patent Rights under this Agreement, VOXELJET shall pay to BEGO within thirty (30) days of conclusion of contract a non-redeemable and non-offsettable advance payment totalling [***].

 

4.2                               Without prejudice to paragraph 4.3, VOXELJET shall furthermore pay a turnover-related licence fee totalling [***] of the Net Selling Price of the Contractual Products to the extent a licenced BEGO patent right is being used in consideration of granting of the Licenced BEGO Patent Rights under this Agreement.

 

4.3                               VOXELJET shall furthermore pay to BEGO a licence fee that is calculated depending on the quantity of Consumables used totalling [***] of the Net Selling Price of Consumables in consideration of the products manufactured in application of the Contractual Processes, to the extent a licenced BEGO patent right is being used. The licence fee according to paragraph 4.3 shall be incurred if and to the extent VOXELJET or a company affiliated with VOXELJET supplies a Third Party who uses a Contractual Product in application of Contractual Processes with Consumables. After payment of the licence fee according to paragraphs 4.2 and 4.3, Third Parties and thus VOXELJET shall not incur any additional licence fee payments with respect to the Contractual Processes that are performed on such a Contractual Product by a Third Party; this means that BEGO to this extent waives its right to assert the Licenced BEGO Patent Rights against Third Parties who acquired Contractual Products from VOXELJET and are using Contractual Processes.

 

4.4                               No fees according to paragraphs 4.2 and 4.3 shall be incurred for Contractual Products that are manufactured for BEGO or companies affiliated with BEGO.

 

4.5                              In the event of sub-licences, this does explicitly not include user licences to Third Parties for the use of the Contractual Products and Contractual Processes according to paragraph

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

9

 

4.3 that are performed on these Contractual Products by these Third Parties, VOXELJET shall pay to BEGO a share of [***] of any licence fees that VOXELJET receives for granting the sub-licence, however only to the extent that the VOXELJET patent rights have not been issued with final and absolute effect or have been revoked or eliminated.

 

Section 5                                             Payment Terms

 

5.1                               Licence fees shall be paid to the accounts to be indicated by the Parties in euros plus the statutory rate of value-added tax, as amended, incurred on it.

 

5.2                               As per the 31st day of the month of December in each calendar year, VOXELJET shall draw up a statement of accounts for the previous calendar year. The first statement of account will comprise all the relevant cases from 1 January 2012 onwards. The invoice shall be sent within four weeks of expiry of the calendar year concerned.

 

5.3                               VOXELJET shall keep books and draw up statements of account for any data that is required for correct and complete accounts. Once every year during VOXELJET’s normal business hours BEGO has the right upon reasonable prior announcement to have VOXELJET’s accounts with respect to the previous calendar year inspected by an independent auditor who is under a professional secrecy obligation. VOXELJET agrees to assume the costs of the auditor should the difference between the statements of account and the auditor’s findings amount to five per cent (5%) or more to BEGO’s detriment. Differential amounts shall be payable and due immediately.

 

5.4                               The licence fees shall be payable by VOXELJET within thirty days of the date of invoice. Reciprocal payments shall be offset against each other. Payment shall be made to the account indicated on the invoice.

 

5.5                               After occurrence of the maturity, every amount shall incur five (5) percentage points interest on top of the applicable base rate.

 

Section 6                                             Obtaining and Maintaining the Licenced Patent Rights

 

6.1                               The Parties have the obligation to pursue the process of issuance for the application for the respective Licenced VOXELJET Patent Rights and/or the Licenced BEGO Patent Rights without time delay and in a proper way and to maintain the Licenced VOXELJET Patent Rights and/or the Licenced BEGO Patent Rights during the term of this Agreement. The Parties agree to take any action that is deemed to be economically reasonable and necessary for issuing or maintaining the Licenced VOXELJET Patent Rights and Licenced BEGO Patent Rights respectively.

 

[***]              Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

10

 

6.2                               Should VOXELJET decide to discontinue the issuing process or prematurely drop or sell a licenced VOXELJET patent already issued, VOXELJET has the duty to notify BEGO in writing of its corresponding intention at least thirty (30) days prior to expiry of the pertinent periods like disclosure periods or time allowed to pay maintenance fees and to submit to BEGO a written offer to take on the licenced VOXELJET patent right concerned free of charge. Should BEGO accept the offer to take on the licenced VOXELJET patent right within thirty (30) days of receipt of this offer, VOXELJET agrees to take any action that is necessary for the transfer of the licenced VOXELJET patent in the patent register. The licence fees relating to the licenced VOXELJET patent taken on by BEGO shall remain unchanged as a result of take-over which means that BEGO shall not increase the licence fees even if the licenced VOXELJET patent was included in the calculation of the licence fee. Should BEGO allow the period of thirty (30) days to pass without accepting the offer to take on the patent, VOXELJET may at its discretion drop the licenced VOXELJET patent concerned. In this case VOXELJET shall not have any claims for damages against BEGO. At VOXELJET’s request BEGO shall grant VOXELJET a non-exclusive gratuitous right to use the licenced VOXELJET patent taken on.

 

6.3                               Should BEGO decide to discontinue the issuing process or prematurely drop or sell a licenced BEGO patent already issued, BEGO has the duty to notify VOXELJET in writing of its corresponding intention at least thirty (30) days prior to expiry of the pertinent periods like disclosure periods or time allowed to pay maintenance fees and to submit to VOXELJET a written offer to take on the licenced BEGO patent right concerned free of charge. Should VOXELJET accept the offer to take on the licenced BEGO patent right within thirty (30) days of receipt of this offer, BEGO agrees to take any action that is necessary for the transfer of the licenced BEGO patent in the patent register. The licence fees relating to the licenced BEGO patent taken on by VOXELJET shall remain unchanged as a result of take-over which means that VOXELJET shall not increase the licence fees even if the licenced BEGO patent was included in the calculation of the licence fee. Should VOXELJET allow the period of thirty (30) days to pass without accepting the offer to take on the patent, BEGO may at its discretion drop the licenced BEGO patent concerned. In this case BEGO shall not have any claims for damages against VOXELJET. VOXELJET shall at BEGO’s request grant BEGO a non-exclusive gratuitous right to use the licenced BEGO patent taken on.

 

6.4                               Every Party has the right to apply for registration of the licence to the licenced patent that was granted in the German patent register or its equivalent abroad at its own expense. The other Party agrees to support the registration and at request shall take any action that may be required to achieve it.

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

11

 

Section 7                                             Defending the Licenced Rights Against Infringement by Third Parties

 

7.1                               The Parties agree to reciprocally notify each other in writing of any infringement of licenced rights of the respective other Party that they may become aware of during the term of this Agreement.

 

7.2                               The Parties may at their discretion enforce claims for infringement by Third Parties.  Should either of the Parties decide to enforce infringement claims, the other Party agrees to make the corresponding declarations to enable such enforcement. A German and English version of the corresponding licence acknowledgement and assignment declaration was annexed to this Agreement as Annex 4.

 

Section 8                                             Warranties

 

8.1                               The Parties reciprocally represent and warrant as follows

 

(i)                                     I am the owner or authorised licensor of the licenced patents concerned.

 

(ii)                                  I have the right to enter into this Agreement and to grant the licences therein granted.

 

(iii)                               I am not aware of the existence of any circumstances which could render the licenced rights concerned invalid or according to which use of such licenced rights could infringe upon Third Party patent rights.

 

8.2                               The Parties do not assume a warranty as to the technical feasibility, technical suitability, commercial marketability, the fitness for production, profitability of production and/or the competitiveness of the licenced rights concerned. The Parties in particular shall not assume neither an express nor an implied warranty or representation as to the success of development and marketing of the Contractual Products. Moreover, the Parties shall not warrant to each other that a patent may be obtained for the licenced rights concerned.

 

8.3                               Warranty claims, if any, shall become statute-barred within [***] of the statutory commencement date of the limitation period.

 

Section 9                                             Confidentiality

 

9.1                               Any Confidential Information that a Party (“Notifying Party”) notifies the other Party of (“Receiving Party”) or discloses to it in any other way on the basis of or in connection with this Agreement may only be used by the Receiving Party for the purposes of this Agreement. The Receiving Party shall not use the Confidential Information received from the Notifying Party for any purposes other than those relating to the Agreement and may

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

12

 

not forward the Confidential Information to Third Parties or make it available to them in any other way without the Notifying Party’s consent.

 

9.2                               The Receiving Party further undertakes to take any reasonable steps and take any precautions that may be necessary for preventing unauthorised use or disclosure of the Confidential Information received from the notifying party. The Receiving Party shall exclusively make the Confidential Information available to its staff, vicarious agents (Erfüllungsgehilfen), consultants, licensees, future licensees and financial investors who need to have knowledge of the Confidential Information received from the Notifying Party so as to enable the Receiving Party to comply with its rights and obligations under this Agreement and it shall only disclose them if and to the extent the staff, vicarious agents, consultants, licensees, future licensees and financial investors concerned have assumed vis-à-vis the Receiving Party an adequate confidentiality undertaking which corresponds to and comprises comparable terms and conditions to this Agreement that prohibit unauthorised use and disclosure of the Confidential Information received from the Notifying Party. The Receiving Party agrees to promptly notify the Notifying Party in writing if and once it has become aware of unauthorised use or disclosure of the Confidential Information received from the Notifying Party and it shall at the Notifying Party’s request take any appropriate action that is required for preventing further unauthorised use or disclosure of the Confidential Information received from the Notifying Party.

 

9.3                               The aforementioned obligations of the Receiving Party under paragraphs 9.1 and 9.2 above shall not apply with respect to information with respect to which the Receiving Party may prove by presenting written documents that such information:

 

(i)                                     at the time of notification by the Notifying Party had already been in the public domain or had subsequently become public knowledge without the Receiving Party’s fault;

 

(ii)                                  at the time of notification by the Notifying Party had already been in the Receiving Party’s possession;

 

(iii)                               had been made available to the Receiving Party by a Third Party without a confidentiality obligation and duty to refrain from using it being imposed;

 

(iv)                              based on a statutory provision or court order needs to be disclosed to public authorities; the Receiving Party, however, shall have the obligation to notify the Notifying Party thereof in due time in writing so as to give the Notifying Party an opportunity to initiate reasonable steps at its discretion so as to prevent the Confidential Information received from becoming generally available; or

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

13

 

(v)                                 have been developed by the Receiving Party independently from and without breaching this Agreement.

 

9.4                               After termination of this Agreement for whatever reason the Receiving Party agrees to return to the Notifying Party any copies of documents and any other material that comprises the Confidential Information received from the Notifying Party or destroy it after having been requested by the Notifying Party to do so. This only excludes copies the Receiving Party is required to keep by law or has the right to keep on the basis of this Agreement. Within thirty (30) days of termination of this Agreement, the Receiving Party shall send to the Notifying Party a written confirmation as to compliance with this paragraph 9.4.

 

9.5                               All the obligations of the Receiving Party under paragraphs 9.1 and 9.2 with respect to the protection of Confidential Information received from the Notifying Party shall also survive termination of this Agreement, whatever the reason for termination.

 

Section 10                                      Term and Termination

 

10.1                        This Agreement shall come into force upon the Effective Date and the term of the Agreement shall go on for as long as a Contractual Product is still governed by a licenced VOXELJET patent right or licenced BEGO patent right in any country within the Territory. Any Contractual Products manufactured and supplied by the Parties and paid for by the customer prior to the commencement date of the Agreement that are governed by a licenced patent claim shall be deemed to have been settled and shall not trigger payment of a licence fee according to paragraphs 4 and 5.

 

10.2                        Should one of the Parties (“Party In Breach”) breach a contractual duty which is of the essence of the Agreement or be in delay with performance of one of its obligations under this Agreement, the other Party (“Party Not In Breach”) shall notify the Party In Breach in writing of the breach of contract and/or the delay in the performance of an obligation and request that the breach of contract and/or delay in performance of an obligation be cured without undue delay. Should the Party In Breach fail to cure the breach of contract or delay in the performance of an obligation within thirty (30) days of receipt of the written notice from the Party Not In Breach, the Party Not In Breach has the right to give to the Party In Breach written notice of termination of this Agreement as a whole or for individual countries located within the Territory or for individual fields of application. Termination of this Agreement shall not affect the right of the Party Not In Breach to assert against the Party In Breach damages as well as any other claims that may be incurred by the Party Not In Breach due to the breach of contract or delay in the performance of the obligation and the resulting premature termination of the Agreement.

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

14

 

A breach of a provision which is of the essence of the Agreement which shall give the respective other Party the right to terminate this Agreement for cause shall exist in particular in the following circumstances:

 

(i)                                     delay with drawing up a statement of account for and/or payment of licence fees,

 

(ii)                                  a Party challenging the other Party’s property rights.

 

10.3                        Furthermore and in supplement to the extraordinary right of termination, every Party has the right to terminate this Agreement for cause i.e. with immediate effect by sending the respective other Party a written termination notice should the assets of the other Party be subjected to bankruptcy or insolvency proceedings.

 

Section 11                                      Legal Consequences of Termination of Agreement

 

11.1                        In the event of termination of this Agreement the licence to the contractual patents entered into under this Agreement shall expire.

 

11.2                        Unless otherwise agreed upon, the Party concerned agrees in the event of termination of this Agreement, for whatever reason, to discontinue without undue delay further manufacturing, production, distribution, marketing and disposal of Contractual Products on the basis of this Agreement. Should the licensing agreement be terminated for reasons which are not attributable to the other Party, the Party concerned shall continue to have the right to deplete and sell off its stocks of Contractual Products within a period of no more than one hundred and twenty (120) days following termination of this Agreement without prejudice to the obligation to pay to BEGO turnover-related licence fees for such sell-off of Contractual Products.

 

11.3                        Termination of this Agreement for whatever reason shall not release the Party concerned from its obligations of paying any licence fees and other fees which have been incurred during the term of the Agreement but remain unpaid upon termination of Agreement and/or are only incurred after the Agreement was terminated.

 

Section 12                                      Final Provisions

 

12.1                        No Party has the right to assign its rights or the performance of its obligations under this Agreement without the other Party’s prior written consent; a Party, however, may only refuse to consent for good cause; no prior written consent must be obtained from the other Party for assignment of rights or performance of obligations under this Agreement to an Affiliated Company or in the context of disposal of all material assets of the Party concerned. As a result of permissible assignment, this Party shall not be released from its

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

15

 

obligations under this Agreement including the obligation to pay licence fees for any Net Selling Prices that the buyer or sub-licensee may generate from the sale of the Contractual Products.

 

12.2                        This Agreement shall be governed by the laws of the Federal Republic of Germany excluding the UN Sales Convention (CISG).

 

12.3                        In case of disputes arising from or in connection with this Agreement or concerning its validity, a final and binding decision will be taken under the arbitration rules of the German Institute of Arbitration (Deutsche Institution für Schiedsgerichtsbarkeit e. V., DIS) and ordinary legal redress shall be excluded. Hamburg shall be the venue of arbitration proceedings. The arbitration tribunal shall be made up of three arbitrators. German law shall be the governing substantive law. German shall be the language relevant for arbitration proceedings.

 

12.4                        The Parties are aware of the risk of one or several of the provisions of this Agreement becoming invalid or nil and void in contrast to what is currently envisaged by the Parties. Also in this case the Parties are willing to exclude every doubt about the validity of this Agreement. Should one or several provisions of this Agreement including this clause be or become invalid or nil and void in part or as a whole or should it turn out that there is a loophole in this Agreement, the Agreement shall therefore in derogation of section 139 German Civil Code (BGB) not only remain valid if in doubt but instead always. The contracting parties agree to replace the invalid or missing provisions by provisions that most closely correspond to the intended commercial purpose of the Agreement.

 

12.5                        In derogation of section 9 the Parties shall make a press release coordinated between them regarding cooperation under this Agreement by which the public will be informed of the fact that the Parties have entered into this licensing agreement - without mentioning any details of the individual terms and conditions.

 

12.6                        This Agreement including its annexes constitutes the overall agreement between the Parties with respect to the subject-matter of the Agreement. This Agreement shall supersede any previous written and verbal agreements that may have been made between the Parties with respect to the subject-matter of agreement. Changes in and amendments of this Agreement shall only be valid and effective if made in writing. This rule shall also apply to a waiver of the written form requirement.

 

 

	
 
    	
/s/ Thomas Kosin
    	
 
    	
 
    	
/s/ Ingo Ederer
    
	
BEGO Medical GmbH
    	
 
    	
VOXELJET technology GmbH
    

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

16

 

Annexes:

 

Annex 1: List of Licenced BEGO Patents

 

·                        EP 2289462 Al: continuous, generative manufacturing process and device

 

·                        DE 20 2011 003 443: device for generative production of three-dimensional components

 

·                        WO 2012 076205 Al: device and process for generative production of three-dimentional components

 

Annex 2: List of Licenced VOXELJET Patents

 

·                        DE 102010015451 Al: process and device for producing three-dimensional objects

 

·                        WO 2011 127897 A2: process and device for producing three-dimensional models

 

Annex 3: Sample Net Selling Price Invoice

 

·                        [***]

 

[***]

 

[***]

 

[***]

 

[***]

 

[***]

 

[***]

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

17

 

 

BEGO Medical GmbH — Postfach -28353 Bremen

voxeljet technology GmbH
 Attn.: Dr. Ingo Ederer
 Paul-Lenz-Straße 1
 86316 Friedberg

 

	
Unser Zeichen:   Lizenzvertrag
    	
 
    	
Tel.: +49 (0) 421 20   28-110
    	
 
    	
24. September 2012
    
	
kosin@bego.com
    	
 
    	
Fax: +49 (0) 421 20 28-44110
    	
 
    	
 
    

 

Confirmation of licence for VOXELJET technology GmbH

 

Dear Dr. Ederer,

 

The undersigned company is the proprietor of the following patents:

 

·                        EP 2289462 Al: Vorrichtung und Verfahren zur kontinuierlichen, generativen Fertigung

 

·                        DE 20 2011 003 443: Vorrichtung zur generativen Herstellung dreidimensionaler Bauteile

 

·                        WO 2012 076205 Al: Vorrichtung und Verfahren zur generativen Herstellung dreidimensionaler Bauteile (“Patents”)

 

According to the licence agreement dated August 21st, 2012 the Friedberg-based firm of VOXELJET technology GmbH [and its Associated Companies] has been granted an exclusive licence in the so-called VOXELJET Field of Use for all those countries in which the Patents have been registered (“Contractual Territories”).

 

VOXELJET technology GmbH and its Associated Company have the right, therefore, to grant sub-licences in its own name to third-parties anywhere within the Contractual Territories.

 

VOXELJET technology GmbH is also entitled to assert any rights deriving from these patents, in its own name and to its own account. Any claims to damages that may have arisen due to infringements of these patents prior to August 21st, 2012 have been assigned to VOXELJET technology GmbH. This assignment of rights is repeated here as a precautionary measure.

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

18

 

	
 Bremen, 24.09.12
    	
 
    	
 
    
	
(Place), (date)
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
  /s/ Thomas   Kosin
    	
 
    	
 
    
	
BEGO Medical GmbH
    	
 
    	
 
    

 

VOXELJET technology GmbH expressly accepts the above assignment a second time.

 

	
Friedberg,
    	
26.09.12
    	
/s/ Ingo Ederer
    	
 
    
	
 
    	
Signature of managing   director
    	
 
    
					

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

19

 

 

BEGO Medical GmbH 
 Mr Christoph Weiss 
 Wilhelm-Herbst-Straße 1 
 28359 Bremen

 

September 27, 2012

 

Confirmation of licence for BEGO Medical GmbH

 

Dear Mr Weiss,

 

The undersigned company is the proprietor of the following patents:

 

·                  DE 102010015451 Al : Verfahren und Vorrichtung zum Herstellen dreidimensionaler Objekte („Patents”)

 

·                  WO 2011 127897 A2: Verfahren und Vorrichtung zum Herstellen dreidimensionaler Modelle

 

According to the licence agreement dated August 21st, 2012 the Bremen-based firm of BEGO Medical GmbH [and its Associated Companies] has been granted an exclusive licence for all those countries in which the Patents have been registered (“Contractual Territories”).

 

BEGO Medical GmbH and its Associated Company have the right, therefore, to grant sub-licences in its own name to third-parties anywhere within the Contractual Territories.

 

{BEGO Medical GmbH is also entitled to assert any rights deriving from these patents, in its own name and to its own account. Any claims to damages that may have arisen due to infringements of these patents prior to August 21st, 2012 have been assigned to BEGO Medical GmbH. This assignment of rights is repeated here as a precautionary measure.}

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

20

 

Page 2 of our letter dated September 27, 2012

 

	
Augsburg, 27.09.2012
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
(Place), (date)
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
  /s/ Ingo Ederer
    	
 
    	
 
    
	
VOXELJET technology GmbH
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
BEGO Medial GmbH expressly accepts the above   assignment a second time.
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Bremen,
    	
           /s/   Thomas Kosin
    	
 
    	
 
    
	
 
    	
Signature of managing director
    	
 
    	
 
    

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

21Exhibit 10.4

 

Z CORPORATION

NONEXCLUSIVE PATENT LICENSE AND SUBLICENSE AGREEMENT 
 WITH VOXELJET

 

This Agreement, effective as of the date set forth above the signatures of the parties below (the “Effective Date”), is between Z Corporation (“Z Corp.”), a Massachusetts corporation, with a principal office at 20 North Avenue, Burlington, MA 01803 and Voxeljet Technology GmbH (“Voxeljet”), a corporation registered in Amtsgericht Augsburg (#HRB 17081), with a principal place of business at Am Mittleren Moos 15, 86167 Augsburg, Germany.

 

RECITALS

 

WHEREAS, The Massachusetts Institute of Technology (M.I.T.) and Z Corp. have previously entered into a Patent License Agreement dated as of December 21, 1994, as amended to date (the “M.I.T. License”), pursuant to which M.I.T. granted to Z Corp. a license to its Three Dimensional Printing patent portfolio (the “M.I.T. Patents”, listed in Appendix A);

 

WHEREAS, Z Corp. has filed its own patents, some of which are of interest to Voxeljet (“Z Corporation Patents”, listed in Appendix A);

 

WHEREAS, Z Corp. is willing to grant to Voxeljet a non-exclusive sublicense to the M.I.T. Patents and a license to the Z Corporation Patents (collectively referred to as “Licensed Patents”) solely for the manufacturing, sale and operation of three dimensional printing equipment for the fabrication of plastic parts subject to specified conditions, and Voxeljet is willing to accept the grant of the license and sublicense subject to such conditions; and

 

WHEREAS, Z Corp. and Voxeljet desire to enter into a license and sublicense agreement upon the terms and conditions hereinafter set forth.

 

NOW, THEREFORE, Z Corp. and Voxeljet hereby agree as follows:

 

1.                                      Definitions.

 

1.1                               “Field” shall means the manufacture, sale and operation of three dimensional printing equipment solely for the fabrication of plastic parts [***].

 

1.2                               “Licensed Product” shall mean any product or part thereof that:

 

(a)                                 absent the license or sublicense granted hereunder, would infringe one or more claims of the Licensed Patents; or

 

(b)                                 is manufactured by using a Licensed Process or that, when used, practices a Licensed Process.

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

1

 

1.3                               “Licensed Process” shall mean any process that, absent the license or sublicense granted hereunder, would infringe one or more claims of the Licensed Patents or which uses a Licensed Product.

 

1.4                               “Licensed Patents” shall mean those patents listed in Appendix A to this Agreement together with

 

(a)                                 any divisionals, continuations, continuation-in-part applications, and continued prosecution applications (and their relevant international equivalents) of the Licensed Patents to the extent the claims of such applications are directed to subject matter specifically described in the resulting patents; and

 

(b)                                 any patents resulting from reissues, reexaminations, or extensions (and their relevant international equivalents) of the patents described in (a) above.

 

1.5                               “Net Sales” shall mean the total amount of all consideration received by Voxeljet from unaffiliated third parties in arm’s length transactions (whether such transaction takes the form of a sale, lease or other use) for Licensed Products and Licensed Processes, less the following:

 

(a)                                 discounts allowed in amounts customary in the trade for quantity purchases, cash payments, prompt payments, wholesalers and distributors;

 

(b)                                 sales, use and excise taxes, tariffs and/or duties directly imposed on any sale of a Licensed Product or Licensed Process;

 

(c)                                  outbound transportation prepaid or allowed; and

 

(d)                                 amounts allowed or credited on returns.

 

1.6                               “Net Royalty Sales” shall mean Net Sales for which Voxeljet pays the royalty as a percentage [***], as described in Section 4.2 (a)-first paragraph, but shall not include Net Sales for which Voxeljet pays the minimum fixed royalty [***] as described in Sections 4.2 (a)-last paragraph, (b) and (c).

 

1.7                               “Term” shall mean the term of this Agreement, which shall commence on the Effective Date and shall remain in effect until the earlier of (i) as to the M.I.T. Patents, the termination of the license to the M.I.T. Patents by Z Corporation or (ii) as to all Licensed Patents, the expiration or abandonment of all issued patents and filed patent applications within the Licensed Patents, unless earlier terminated in accordance with the provisions of this Agreement.

 

2.                                      Grant of Rights.

 

2.1                               License Grants.  Subject to the terms of this Agreement, Z Corp. hereby grants to Voxeljet for the Term a worldwide, nonexclusive license or sublicense under the Licensed Patents to develop, make, have made, use, sell, lease, offer to sell, offer to lease, and import

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

2

 

Licensed Products in the Field and to develop and perform Licensed Processes in the Field. Voxeljet shall not have the right to sublicense the Licensed Patents.

 

2.2                               No Additional Rights.  Nothing in this Agreement shall be construed to confer any rights upon Voxeljet by implication, estoppel, or otherwise as to any technology or patent rights of Z Corp. or M.I.T. or any other entity other than the Licensed Patents, regardless of whether such technology or patent rights shall be dominant or subordinate to any of the Licensed Patents.

 

3.                                      Voxeljet Diligence Obligations.

 

3.1                               Voxeljet agrees to demonstrate reasonable efforts to commercialize the technology represented by the Licensed Patents in the Field.

 

3.2                               Voxeljet agrees to insert the following use restriction language verbatim in all of its Quotations, Acceptance of Purchase Orders, and all other equivalent documentation in connection with any sale or lease of the equipment by Voxeljet to its customers:

 

“USE OF EQUIPMENT

 

The Equipment (including any use of the Equipment), is subject to limitations imposed under a Nonexclusive Patent Sublicense Agreement between Voxeljet and Z Corporation, and is to be used solely for the fabrication of plastic parts [***].  Other uses of the Equipment are strictly prohibited and may expose the user to liability for patent infringement.”

 

4.                                      Fees and Payment Terms.

 

For the rights, privileges and license and sublicense granted hereby, Voxeljet shall pay the following amounts to Z Corp. in the manner hereinafter provided until the earlier of the expiration or termination of the last of the Licensed Patents or until the end of the Term:

 

4.1                               Initial License Fee.  Voxeljet shall pay to Z Corp. a one-time license/sublicense fee of [***], which shall be paid as follows:  [***] of the Effective Date; [***] of the Effective Date; [***] of the Effective Date; and [***] of the Effective Date.

 

4.2                               Royalties.  Voxeljet shall pay to Z Corp. a running royalty in an amount equal to

 

(a)                                 [***]

 

Subject in each instance to a minimum royalty of [***] for each 3D printer that is a Licensed Product.  For sales made after [***], such minimum royalty shall be [***] for each 3D printer that is a Licensed Product.

 

(b)                                 If Voxeljet uses a 3D printer that is a Licensed Product, other than a 3D printer purchased from Z Corp., for making parts for internal use or for sale to third parties, Voxeljet shall pay to Z Corp. a royalty of [***], which amount will be credited against the royalty due under subsection 4.2(a) above if the Licensed Product is subsequently sold by Voxeljet.  For a 3D printer that is a

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

3

 

Licensed Product, other than a 3D printer purchased from Z Corp., put into use after [***] for making parts for internal use or for sale to third parties, such royalty shall instead be [***].  No further royalty shall be payable by Voxeljet to Z Corp. upon use and sale of parts made by a 3D printer that is a Licensed Product beyond the royalty described above.

 

(c)                                  If Voxeljet purchases a three dimensional printer that is a Licensed Product or related equipment from Z Corp. and modifies it for sale in the Field, Voxeljet shall pay to Z Corp., in addition to the purchase price for the equipment, a royalty of [***].  No further royalty shall be payable by Voxeljet to Z Corp. upon any subsequent sale of the equipment or sale of products made from the equipment to a third party.  Z Corp. shall not be obligated to provide any warranty or service agreement with respect to any three dimensional printer or related equipment, parts or accessories which are purchased, modified or re-sold by Voxeljet.

 

5.                                      Reports and Records.

 

5.1                               Voxeljet shall keep full, true and accurate books of account containing all particulars that may be necessary for the purpose of showing the amounts payable to Z Corp. under this Agreement.  Said books of account shall be kept at Voxeljet’s principal place of business.  Said books of account and the supporting data shall be open at all reasonable times for [***] following the end of the calendar year to which they pertain to the confidential inspection, upon at least one week written notice, by a designated representative of Z Corp. for the purpose of verifying Voxeljet’s royalty statement or compliance in other respects with this Agreement. Should any such inspection result in the discovery of a greater than Ten Percent (10%) discrepancy to Z Corp.’s detriment, as verified by a designated independent auditor of Z Corp., Voxeljet shall be required to pay the full cost of such inspection.  Z Corp. shall also have the right, upon at least 48 hours written notice, during normal business hours to inspect the operations and records of Voxeljet to ensure that it remains in compliance with the provisions of this Agreement.

 

5.2                               Voxeljet shall deliver to Z Corp. no later than thirty (30) days following the end of each calendar quarter during the Term, commencing with the calendar quarter ending September 30, 2004, true and accurate reports showing all Net Sales that occurred during the quarter in question.  The reports shall include at a minimum:

 

(a)                                 the number of Licensed Products manufactured, leased or sold by Voxeljet during such quarter, as well as the customer name, location and intended use;

 

(b)                                 the total Net Sales, Net Royalty Sales and Cumulative Net Royalty Sales, during such quarter, noting the applicable deductions provided in Section 1.5;

 

(c)                                  running royalties due under Sections 4.2 (a) and (b); and

 

(d)                                 total royalties due under this Agreement with respect to such calendar quarter.

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

4

 

5.3                               With each such report, Voxeljet shall pay to Z Corp. the royalties due and payable under this Agreement.  If no royalties shall be due, Voxeljet shall so report.  Any royalty payable under Section 4.2(c) shall be payable at the time such three dimensional printer or other equipment is purchased from Z Corp.

 

5.4                               All payments under this Agreement should be made payable to “Z Corporation” and sent to the address identified in Section 14.1.  Each payment should reference this Agreement and identify the obligation under this Agreement that the payment satisfies.  All payments due under this Agreement shall be payable in United States dollars.  Any payments by Voxeljet that are not paid on or before the date such payments are due under this Agreement shall bear interest until payment is made, to the extent permitted by law, at the rate of two percentage points above the Prime Rate of interest as reported in the Wall Street Journal on the date payment is due.  The payment of such interest shall not prevent Z Corp. from pursuing any other remedy it may have as the result of any late payment made by Voxeljet.

 

6.                                      Patent Prosecution.

 

6.1                               Responsibility for M.I.T. Patents.  Voxeljet acknowledges that M.I.T. shall have sole discretion to apply for, seek issuance of, maintain, or abandon the M.I.T. Patents during the term of this Agreement.

 

6.2                               Responsibility for Z Corporation Patents.  Voxeljet acknowledges that Z Corporation shall have sole discretion to apply for, seek issuance of, maintain, or abandon the Z Corporation Patents during the term of this Agreement.

 

6.3                               Payment of Expenses.  Payment of all fees and costs, including attorneys fees, incurred by M.I.T. relating to the prosecution and maintenance of the M.I.T. Patents are the responsibility of M.I.T. and licensees of the M.I.T. Patents as they exist from time to time.  Voxeljet shall be responsible for [***] of such expenses, which represents significantly less than Voxeljet’s pro-rata share of such expenses, to be paid as follows: [***] of the Effective Date; and [***] of the Effective Date.  No further amount relating to payment of patent expenses shall be due or owing by Voxeljet during the term of this Agreement.

 

7.                                      Infringement.

 

7.1                               Notification of Infringement.  If it becomes so aware, Voxeljet shall inform Z Corp. and M.I.T. promptly in writing of any alleged infringement of the Licensed Patents by a third party and of any available evidence thereof.

 

7.2                               Right to Prosecute.  Voxeljet acknowledges that Z Corp. and M.I.T. shall have the right, but shall not be obligated, to prosecute at their own expense all infringements of the M.I.T. Patents.  Z Corp. shall have the right, but shall not be obligated, to prosecute at its own expense all infringements of the Z Corporation Patents.

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

5

 

7.3                               Cooperation.  In any infringement suit which M.I.T. or Z Corporation may institute to enforce the M.I.T. or Z Corporation Patents, Voxeljet shall, at Z Corp.’s expense, cooperate in all respects and, to the extent reasonably possible, have its then existing employees testify, and help locate former employees, when requested and make available relevant records, papers, information, samples, specimens, and the like, to the extent that they still exist.

 

8.                                      Indemnification and Insurance.

 

8.1                               Indemnification.

 

(a)                                 Indemnity.  Voxeljet shall indemnify, defend, and hold harmless M.I.T. and Z Corp. and their trustees, directors, officers, faculty, students, employees, and agents and their respective successors, heirs and assigns (the “Indemnitees”), against any liability, damage, loss, or expense (including reasonable attorneys fees and expenses) incurred by or imposed upon any of the Indemnitees in connection with any claims, suits, actions, demands or judgments arising out of any theory of liability (including without limitation actions in the form of tort, warranty, or strict liability and regardless of whether such action has any factual basis) concerning any product, process, or service that is made, used, sold, imported, or performed pursuant to any right or license or sublicense granted under this Agreement.

 

(b)                                 Procedures.  The Indemnitees agree to provide Voxeljet with prompt written notice of any claim, suit, action, demand, or judgment for which indemnification is sought under this Agreement.  Voxeljet agrees, at its own expense, to provide attorneys reasonably acceptable to M.I.T. and Z Corp. to defend against any such claim.  The Indemnitees shall cooperate fully with Voxeljet in such defense and will permit Voxeljet to conduct and control such defense and the disposition of such claim, suit, or action (including all decisions relative to litigation, appeal, and settlement); provided, however, that any Indemnitee shall have the right to retain its own counsel, at the expense of Voxeljet, if representation of such Indemnitee by the counsel retained by Voxeljet would be inappropriate because of actual or potential differences in the interests of such Indemnitee and any other party represented by such counsel.  Voxeljet agrees to keep M.I.T. and Z Corp. informed of the progress in the defense and disposition of such claim and to consult with M.I.T. and Z Corp. with regard to any proposed settlement.

 

8.2                               Insurance.  Voxeljet shall obtain and carry in full force and effect commercial general liability insurance, including product liability and errors and omissions insurance which shall protect Voxeljet and Indemnitees with respect to events covered by Section 8.1(a) above.  Such insurance (i) shall be issued by an insurer licensed to practice in Germany, (ii) shall be endorsed to include product liability coverage, and (iii) shall require thirty (30) days written notice to be given to M.I.T. and Z Corp. prior to any cancellation or material change thereof.  The limits of such insurance shall not be less than [***] per occurrence with an aggregate of [***] for bodily injury including death; [***] per occurrence with an aggregate of [***] for property damage; and [***] per occurrence with an aggregate of [***] for errors and omissions.  Voxeljet shall provide M.I.T. and Z Corp. with Certificates of Insurance evidencing compliance with this Section.  Voxeljet shall continue to maintain such insurance or self-insurance after the expiration or termination of this Agreement during any period in which Voxeljet continues (i) to make, use, or

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

6

 

sell a product that was a Licensed Product under this Agreement or (ii) to perform a service that was a Licensed Process under this Agreement, and thereafter for a period of [***].

 

9.                                      No Representations or Warranties.

 

NEITHER M.I.T. NOR Z CORP. MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE PATENT RIGHTS, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, VALIDITY OF PATENT RIGHTS CLAIMS, WHETHER ISSUED OR PENDING, AND THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE.  Specifically, and not to limit the foregoing, M.I.T. and Z Corp. make no warranty or representation (i) regarding the validity or scope of the M.I.T. Patents, and (ii) that the exploitation of the M.I.T. Patents or any Licensed Product or Licensed Process will not infringe any patents or other intellectual property rights.

 

IN NO EVENT SHALL M.I.T., Z CORP., OR VOXELJET (EXCEPT AS PROVIDED IN SECTION 8.1), THEIR TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES, BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGES OR INJURY TO PROPERTY AND LOST PROFITS, REGARDLESS OF WHETHER M.I.T., Z CORP., OR VOXELJET SHALL BE ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY OF THE FOREGOING.

 

10.                               Assignment.

 

This Agreement is personal to Voxeljet and no rights or obligations may be assigned or otherwise transferred by Voxeljet without the prior written consent of Z Corp., which consent may be denied in Z Corp.’s absolute discretion.  Z Corp. acknowledges that Voxeljet may wish to assign this Agreement in the event of an “Acquisition” (as such term is defined below) of Voxeljet.  Z Corp. has no conceptual problem with such assignment as long as it is not counter to Z Corp.’s own business interests.  Because it is impossible to foresee every possible situation, Z Corp. shall have the right to terminate this Agreement by written notice to Voxeljet upon any Acquisition of Voxeljet, but, before taking such action, agrees to consider Voxeljet’s interests as well as its own in making the decision whether to terminate this Agreement.  Ultimately, Z Corp. shall make the decision based on its own business interests.  For purposes of this Section 10, the term “Acquisition” means (a) a sale, merger or consolidation in a single transaction or series of related transactions in which securities possessing more than 50% of the total combined voting power of Voxeljet’s outstanding securities are transferred to a person or persons different from the persons who held those securities immediately prior to such transaction, or (b) the sale, transfer, or other disposition of all or substantially all of Voxeljet’s assets to one or more persons (other than any wholly owned subsidiary of Voxeljet) in a single transaction or series of related transactions.

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

7

 

11.                               General Compliance with Laws.

 

11.1                        Compliance with Laws.  Voxeljet shall use reasonable commercial efforts to comply with all commercially material local, state, federal, and international laws and regulations relating to the development, manufacture, use, and sale of Licensed Products and Licensed Processes.

 

11.2                        Export Control.  Voxeljet shall comply with all applicable laws and regulations controlling the export of certain commodities and technical data, including without limitation all U.S. Export Administration Regulations of the United States Department of Commerce.  Among other things, these laws and regulations prohibit or require a license for the export of certain types of commodities and technical data to specified countries.  Voxeljet hereby gives written assurance that it will comply with all United States export control laws and regulations, that it bears sole responsibility for its violations of such laws and regulations and that it will indemnify, defend, and hold Z Corp. and M.I.T. harmless (in accordance with Section 8.1) for the consequences of any such violation.

 

11.3                        Non-Use of Z Corp. or M.I.T. Name.  Voxeljet shall not use the name of “Z Corporation”, “Massachusetts Institute of Technology,” “Lincoln Laboratory” or any variation, adaptation, or abbreviation thereof, or of any of their respective officers, directors, trustees, faculty, students, employees, or agents, or any trademark owned by Z Corp. or M.I.T., or any terms of this Agreement in any promotional material or other public announcement or disclosure without the prior written consent of Z Corp. and M.I.T.  The foregoing notwithstanding, without the consent of Z Corp. and M.I.T., Voxeljet may state that it is nonexclusively licensed or sublicensed by Z Corp. under one or more of the patents and/or patent applications comprising the M.I.T. or Z Corporation Patents.

 

11.4                        Marking of Licensed Products.  To the extent commercially feasible and consistent with prevailing business practices, Voxeljet shall mark all Licensed Products that are manufactured or sold under this Agreement or literature that accompanies the Licensed Products with the number of each issued patent under the Licensed Patents that applies to such Licensed Product.

 

12.                               Termination.

 

12.1                        Voluntary Termination by Voxeljet.  Voxeljet shall have the right to terminate this Agreement, for any reason, (i) upon at least six (6) months prior written notice to Z Corp., such notice to state the date at least six (6) months in the future upon which termination is to be effective, and (ii) upon payment of all amounts due to Z Corp. through such termination effective date.

 

12.2                        Cessation of Business.  If Voxeljet ceases to carry on its business related to this Agreement, Z Corp. shall have the right to terminate this Agreement immediately upon written notice to Voxeljet.

 

12.3                        Termination for Default.

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

8

 

(a)                                 Nonpayment.  In the event Voxeljet fails to pay any amounts due and payable to Z Corp. hereunder, and fails to make such payments within thirty (30) days after receiving written notice of such failure, in addition to all other rights and remedies available to Z Corp. under applicable law or this Agreement, Z Corp. may terminate this Agreement immediately upon written notice to Voxeljet.

 

(b)                                 Material Breach.  In the event Voxeljet commits a material breach of its obligations under this Agreement, except for breach as described in Section 12.3(a), and fails to cure that breach within thirty (30) days after receiving written notice thereof, in addition to all other rights and remedies available to Z Corp. under applicable law or this Agreement, Z Corp. may terminate this Agreement immediately upon written notice to Voxeljet.

 

(c)                                  Liquidated Damages.  In the event Voxeljet (or any third party who directly or indirectly acquires the Licensed Product or the rights to manufacture, use, sell or lease the Licensed Product or the Licensed Process from Voxeljet) sells, leases or uses any Licensed Product or Licensed Process outside the Field, Voxeljet shall immediately pay to Z Corp. as liquidated damages and not as a penalty, a payment of [***] with respect to each such Licensed Product.

 

(d)                                 Late Charge.  If Voxeljet fails to pay when due any royalty or other amount or charge which Voxeljet is obligated to pay under the terms of this Agreement, then Voxeljet shall pay Z Corp. a late charge equal to [***] of the royalty or other payment calculated from the due date.  Voxeljet acknowledges that any late payment under this Agreement will cause Z Corp. to lose the use of that money and incur costs and expenses not contemplated under this Agreement including, without limitation, administrative costs and processing and accounting expenses, the exact amount of which is extremely difficult to ascertain.  Voxeljet and Z Corp. agree that this late charge represents a reasonable estimate of such costs and expenses and is fair compensation to Z Corp. for the loss suffered as a result of such late payment by Voxeljet.  The late charge is not intended to cover Z Corp’s attorneys’ fees and costs relating to delinquent payments.  Acceptance of any late charge shall not constitute a waiver of Voxeljet ‘s default with respect to such late payment by nor prevent Z Corp. from exercising any other rights or remedies available to Z Corp. under this Agreement.  In no event shall this provision for the imposition of a late charge be deemed to grant to Voxeljet a grace period or an extension of time within which to pay any amount due hereunder or prevent Z Corp. from exercising any right or remedy available to Z Corp. upon Voxeljet’s failure to pay such amount when due.

 

12.4                        Effect of Termination.

 

(a)                                 Survival.  The following provisions shall survive the expiration or termination of this Agreement:  Articles 1, 5, 8, 9, 11, 12, 13 and 14.

 

(b)                                 Pre-termination Obligations.  In no event shall termination of this Agreement release Voxeljet from the obligation to pay any amounts that became due under this Agreement on or before the effective date of termination.

 

13.                               Dispute Resolution.

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

9

 

13.1                        Mandatory Procedures.  The parties agree that any dispute arising out of or relating to this Agreement shall be resolved solely by means of the procedures set forth in this Article, and that such procedures constitute legally binding obligations that are an essential provision of this Agreement.  If either party fails to observe the procedures of this Article, as may be modified by their written agreement, the other party may bring an action for specific performance of these procedures in any court of competent jurisdiction.

 

13.2                        Equitable Remedies.  Although the procedures specified in this Article are the sole and exclusive procedures for the resolution of disputes arising out of or relating to this Agreement, either party may seek a preliminary injunction or other provisional equitable relief if, in its reasonable judgment, such action is necessary to avoid irreparable harm to itself or to preserve its rights under this Agreement.

 

13.3                        Dispute Resolution Procedures.

 

(a)                                 Mediation.  In the event any dispute, whether arising out of or relating to this Agreement remains unresolved within sixty (60) days from the date the affected party informed the other party of such dispute, either party may initiate mediation upon written notice to the other party (“Notice Date”), whereupon both parties shall be obligated to engage in a mediation proceeding under the then current Center for Public Resources (“CPR”) Model Procedure for Mediation of Business Disputes (http://www.cpradr.org), except that specific provisions of this Article shall override inconsistent provisions of the CPR Model Procedure.  The mediator will be a Registered United States Patent Attorney selected from the CPR Panels of Neutrals.  If the parties cannot agree upon the selection of a mediator within fifteen (15) business days after the Notice Date, then upon the request of either party, the CPR shall appoint the mediator.  The parties shall attempt to resolve the dispute through mediation until the first of the following occurs:  (i) the parties reach a written settlement; (ii) the mediator notifies the parties in writing that they have reached an impasse; (iii) the parties agree in writing that they have reached an impasse; or (iv) the parties have not reached a settlement within sixty (60) days after the Notice Date.

 

(b)                                 Trial Without Jury.  If the parties fail to resolve the dispute through mediation, or if neither party elects to initiate mediation, each party shall have the right to pursue any other remedies legally available to resolve the dispute, provided, however, that the parties expressly waive any right to a jury trial in any legal proceeding under this Article.

 

13.4                        Performance to Continue.  Each party shall continue to perform its undisputed obligations under this Agreement pending final resolution of any dispute arising out of or relating to this Agreement; provided, however, that a party may suspend performance of its undisputed obligations during any period in which the other party fails or refuses to perform its undisputed obligations.  Nothing in this Article is intended to relieve Voxeljet from its obligation to make undisputed payments pursuant to this Agreement.

 

13.5                        Statute of Limitations.  The parties agree that all applicable statutes of limitation and time-based defenses (such as estoppel and laches) shall be tolled while the procedures set forth in

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

10

 

Sections 12.3(a) are pending.  The parties shall cooperate in taking any actions necessary to achieve this result.

 

14.                               Miscellaneous.

 

14.1                        Notice.  Any notices required or permitted under this Agreement shall be in writing, shall specifically refer to this Agreement, and shall be sent by hand, recognized national overnight courier, confirmed facsimile transmission, electronic mail with confirmation statement from the other side, or registered or certified mail, postage prepaid, return receipt requested, to the following addresses or facsimile numbers of the parties:

 

	
If to Z Corp:
    	
 
    	
Z   Corporation
    
	
 
    	
 
    	
20   North Avenue
    
	
 
    	
 
    	
Burlington,   MA 01803
    
	
 
    	
 
    	
Attention:   CEO
    
	
 
    	
 
    	
Tel:   (781) 852-5005
    
	
 
    	
 
    	
Fax:   (781) 852-5100
    
	
 
    	
 
    	
 
    
	
If to M.I.T.:
    	
 
    	
Technology   Licensing Office, Room NE25-230
    
	
 
    	
 
    	
Massachusetts   Institute of Technology
    
	
 
    	
 
    	
77   Massachusetts Avenue
    
	
 
    	
 
    	
Cambridge,   MA 02139-4307
    
	
 
    	
 
    	
Attention:   Director
    
	
 
    	
 
    	
Tel:   (617) 253-6966
    
	
 
    	
 
    	
Fax:   (617) 258-6790
    
	
 
    	
 
    	
 
    
	
If to Voxeljet:
    	
 
    	
Voxeljet   Technology GmbH
    
	
 
    	
 
    	
Am   Mittleren Moos 15
    
	
 
    	
 
    	
86167   Augsburg
    
	
 
    	
 
    	
Germany
    
	
 
    	
 
    	
Attention:   CEO
    
	
 
    	
 
    	
Tel: +49 (0) 821 74 83 100
    
	
 
    	
 
    	
Fax:   +49 (0) 821 74 83 111
    

 

All notices under this Agreement shall be deemed effective upon receipt.  A party may change its contact information immediately upon written notice to the other party in the manner provided in this Section.

 

14.2                        Governing Law; Consent to Jurisdiction.  This Agreement and all disputes arising out of or related to this Agreement, or the performance, enforcement, breach or termination hereof, and any remedies relating thereto, shall be construed, governed, interpreted and applied in accordance with the laws of the Commonwealth of Massachusetts, U.S.A., without regard to conflict of laws principles, except that questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent shall have been granted. Any dispute which may arise out of or in connection with this Agreement shall be adjudicated

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

11

 

before a court located in Boston, Massachusetts and the parties hereby submit to the exclusive jurisdiction of the courts of the Commonwealth of Massachusetts located in Boston, Massachusetts and of the federal courts in Boston, Massachusetts with respect to any action or legal proceeding commenced by any party, and irrevocably waive any objection they now or hereafter may have respecting the venue of any such action or proceeding brought in such a court or respecting the fact that such court is an inconvenient forum, relating to or arising out of this Agreement, and the undersigned each consents to the service of process in any such action or legal proceeding by means of express courier and facsimile transfer, return receipt requested, in care of the address set forth below or such other address as each shall furnish in writing to the other parties hereto.  In the event any such action is brought, whether at law or in equity, then the prevailing party shall be paid its reasonable attorney’s fees, expenses and disbursements arising out of such action.

 

14.3                        Force Majeure.  Neither party will be responsible for delays resulting from causes beyond the reasonable control of such party, including without limitation fire, explosion, flood, war, strike, or riot, provided that the nonperforming party uses commercially reasonable efforts to avoid or remove such causes of nonperformance and continues performance under this Agreement with reasonable dispatch whenever such causes are removed; provided, however, that force majeure shall never excuse any delay by Voxeljet in making all payments under this Agreement in a timely manner.

 

14.4                        Amendment and Waiver.  This Agreement may be amended, supplemented, or otherwise modified only by means of a written instrument signed by both parties.  Any waiver of any rights or failure to act in a specific instance shall relate only to such instance and shall not be construed as an agreement to waive any rights or fail to act in any other instance, whether or not similar.

 

14.5                        Severability.  In the event that any provision of this Agreement shall be held invalid or unenforceable for any reason, such invalidity or unenforceability shall not affect any other provision of this Agreement, and the parties shall negotiate in good faith to modify the Agreement to preserve (to the extent possible) their original intent.

 

14.6                        Binding Effect.  This Agreement shall be binding upon and inure to the benefit of the parties and their respective permitted successors and assigns.

 

14.7                        Headings.  All headings are for convenience only and shall not affect the meaning of any provision of this Agreement.

 

14.8                        Entire Agreement.  This Agreement constitutes the entire agreement between the parties with respect to its subject matter and supersedes all prior agreements or understandings between the parties relating to its subject matter.

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized representatives.

 

The EFFECTIVE DATE of this Agreement is August 16, 2004.

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

12

 

	
Z Corporation
    	
Voxeljet Technology GmbH
    
	
 
    	
 
    
	
By:
    	
/s/   Marina Hatsopoulos
    	
By:
    	
/s/   Ingo Ederer
    
	
Name:
    	
Marina   Hatsopoulos
    	
Name:
    	
Ingo   Ederer
    
	
Title:
    	
CEO
    	
Title:
    	
CEO
    
	
 
    	
 
    
	
Approved   as of the Effective Date:
    	
 
    
	
The Massachusetts Institute of Technology
    	
 
    
	
By:
    	
/s/   John H. Turner, Jr.
    	
 
    
	
Name:.
    	
John   H. Turner, Jr
    	
 
    
	
Title:
    	
Associate   Director
    	
 
    
	
 
    	
Technology   Licensing Office
    	
 
    
					

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

13

 

Appendix A

 

Licensed Patents

 

M.I.T. Patents

 

1)                                     M.I.T. Case No. 4972

Canada Patent No. 2031562, Issued November 22, 1994

European Patent Convention Patent No. 0431924, Issued January 31, 1996

France Patent No. 0431924, Issued January 31, 1996

Germany Patent No. P69025147.5, Issued January 31, 1996

Italy Patent No. 0431924, Issued January 31, 1996

Japan Patent No. 2729110, Issued December 12, 1997

Sweden Patent No. 0431924, Issued January 31, 1996

United Kingdom Patent No. 0431924, Issued January 31, 1996

United States of America Patent No, 5204055, Issued April 20, 1993

United States of America Patent No. 5340656, Issued August 23, 1994

“Three-Dimensional Printing Techniques”

by Michael J. Cima, John S. Haggerty, Emanuel M. Sachs and Paul A. Williams

 

2)                                     M.I.T. Case No. 5567

Canada Patent No. 2136748, Issued August 14, 2001

European Patent Convention Patent No. 0644809, Issued July 25, 2001

European Patent Convention Serial No. 00204516.9, Filed June 4, 1993

France Patent No. 0644809, Issued July 25, 2001

Germany Patent No. 0644809, Issued July 25, 2001

Japan Patent No. 2862674, Issued December 11, 1998

United Kingdom Patent No. 0644809, Issued July 25, 2001

United States of America Patent No. 5387380, Issued February 7, 1995

“Three-Dimensional Printing Techniques”

by David Brancazio, James F. Bredt, Michael J. Cima, Alain Curodeau, Tailin Fan, Satbir Khanuja, Alan J. Lauder, Sang-Joon J. Lee, Steven P. Michaels, Emanuel M. Sachs and Harald Tuerck

 

Z Corporation Patents

 

1)                                     US 5,902,441

“Method of Three-Dimensional Printing”

 

2)                                     US 6,007,318

“Method and Apparatus for Prototyping a Three-Dimensional Object”

 

3)                                     US 6,416,850

“Three-Dimensional Printing Materials System”

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

14

 

4)                                     WO 2001/34371 (Z Corp. Reference: “Materials 8”)

“Material System and Methods of Three-Dimensional Printing”

 

5)                                     WO 2001/78969 (Z Corp. Reference: “Materials 10”)

“Compositions for Three-Dimensional Printing of Solid Objects”

US 2001/0050031

“Compositions for Three-Dimensional Printing of Solid Objects”

 

[***]                   Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]